Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

The neuropathological effects of antipsychotic drugs

Harrison, P. J. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00065-1 · Cited by 139

Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action

Javitt, D. C., Duncan, L., Balla, A., & Sershen, H. W. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001552 · Cited by 138

Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant Schizophrenia

Litman, R. E., Su, T., Potter, W. Z., Hong, W. W., & Pickar, D. (1996) · The British Journal of Psychiatry · doi:10.1192/bjp.168.5.571 · Cited by 137

An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function

Fone, K. C. F. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.061 · Cited by 135

Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies

Goldberg, T. E., Keefe, R. S. E., GOLDMAN, R. S., Robinson, D. G., & Harvey, P. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.211 · Cited by 135

5-HT2 Receptor Antagonism Reduces Hyperactivity Induced by Amphetamine, Cocaine, and MK-801 But Not D1 Agonist C-APB

O‘Neill, M. F., Heron-Maxwell, C., & Shaw, G. (1999) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00240-8 · Cited by 134

Quality of life as a predictor for change in disability in MS

Nortvedt, M. W., Riise, T., Myhr, K., & Nyland, H. (2000) · Neurology · doi:10.1212/wnl.55.1.51 · Cited by 134

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.

Siuciak, J., Chapin, D., McCarthy, S. A., Guanowsky, V., Brown, J. A., Chiang, P., Marala, R., Patterson, T., Seymour, P., Swick, A., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.07.024 · Cited by 132

Muscarinic Receptors as a Target for Drugs Treating Schizophrenia

Bymaster, F. P., Felder, C. C., Ahmed, S., & McKinzie, D. L. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606249 · Cited by 131

Current and Novel Approaches to the Drug Treatment of Schizophrenia

Rowley, M., Bristow, L. J., & Hutson, P. H. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0002432 · Cited by 128

Occupancy of Striatal and Extrastriatal Dopamine D2 Receptors by Clozapine and Quetiapine

KESSLER, R. M., Ansari, M. S., Riccardi, P., Li, R., Jayathilake, K., Dawant, B. M., & Meltzer, H. Y. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301108 · Cited by 128

The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine?s actions?

Davies, M. A., Compton-Toth, B. A., Hufeisen, S. J., Meltzer, H. Y., & Roth, B. L. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2017-1 · Cited by 128

Another view of therapy for cognition in schizophrenia

Carpenter, W. T., & Gold, J. M. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01399-9 · Cited by 127

NK3 receptor antagonists: the next generation of antipsychotics?

Spooren, W. P. J. M., Riemer, C., & Meltzer, H. Y. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1905 · Cited by 124

Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating

Feifel, D., & Reza, T. L. (1999) · Psychopharmacology · doi:10.1007/s002130050811 · Cited by 123

Selective α7 Nicotinic Acetylcholine Receptor Ligands

Mazurov, A. A., Hauser, T. A., & Miller, C. H. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706777442011 · Cited by 121

Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis

Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Rock, S. L., Woolson, S., Tohen, M. F., Tollefson, G. D., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.022 · Cited by 121

Effects of the 5-HT7 receptor antagonist SB-258741 in animal models for schizophrenia

Pouzet, B., Didriksen, M., & Arnt, J. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00744-4 · Cited by 120

Cognitive dysfunction in neuropsychiatric disorders: Selected serotonin receptor subtypes as therapeutic targets

Terry, A. V., Buccafusco, J. J., & Wilson, C. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.12.006 · Cited by 120

5-HT3 Receptors

Costall, B., & Naylor, R. J. (2004) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007043482624 · Cited by 120

Schizophrenia: New Pathological Insights and Therapies

Jarskog, L. F., Miyamoto, S., & Lieberman, J. A. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.060904.084114 · Cited by 120

Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Correlations with Hippocampal Neuronal Activity

Hampson, R. E., Rogers, G. A., LYNCH, G. S., & Deadwyler, S. A. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-07-02748.1998 · Cited by 117

SL65.0155, A Novel 5-Hydroxytryptamine4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties

Moser, P. C., Bergis, O. E., Jegham, S., Lochead, A. W., Duconseille, E., Terranova, J.-P., Caille, D., Berque‐Bestel, I., Lezoualc’h, F., Fischmeister, R., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034249 · Cited by 116

Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia

Simpson, M. D. C., Lubman, D. I., Slater, P., & Deakin, J. F. W. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00026-7 · Cited by 115

Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients

Bressan, R. A., Erlandsson, K., JONES, H. M., Mulligan, R. S., Flanagan, R. J., Ell, P. J., & Pilowsky, L. S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1413 · Cited by 115

Guanfacine treatment of cognitive impairment in schizophrenia

Friedman, J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00249-4 · Cited by 113

Varenicline-Induced Manic Episode in a Patient With Bipolar Disorder

Kohen, I., & Kremen, N. J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010173 · Cited by 113

Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial

Shim, J.-C., Jung, D.-U., Jung, S. S., Seo, Y.-S., Cho, D.-M., Lee, J.-H., Lee, S.-W., Kong, B.-G., Kang, J.-W., Oh, M., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.238 · Cited by 112

Brain histamine and schizophrenia: Potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649

Ligneau, X., Landais, L., Perrin, D., Piriou, J., Uguen, M., Denis, E., Robert, P., Parmentier, R., Anaclet, C., Lin, J., et al. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.023 · Cited by 110

Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial

Akhondzadeh, S., Mohammadi, N., Noroozıan, M., Karamghadiri, N., Ghoreishi, A., Jamshidi, A. H., & Forghani, S. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.004 · Cited by 109

Thymosthenic Agents, A Novel Approach in the Treatment of Schizophrenia

Gelders, Y. G. (1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000295950 · Cited by 108

Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder

Smith, R. C., Lindenmayer, J., Davis, J. M., Cornwell, J. A., Noth, K., Gupta, S., Sershen, H. W., & Lajtha, Á. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.02.001 · Cited by 107

Effects of an Alpha 7-Nicotinic Agonist on Default Network Activity in Schizophrenia

Tregellas, J. R., Tanabe, J., Rojas, D. C., Shatti, S., D, A. O. M., Johnson, L. L., Martín, L., Soti, F. S., Kem, W. R., Leonard, S. S., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.004 · Cited by 106

Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy

Wadenberg, M.-L., & Ahlenius, S. (1991) · Journal of Neural Transmission · doi:10.1007/bf01244451 · Cited by 106

Minocycline Attenuates Hyperlocomotion and Prepulse Inhibition Deficits in Mice after Administration of the NMDA Receptor Antagonist Dizocilpine

Zhang, L., Shirayama, Y., Iyo, M., & Hashimoto, K. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301313 · Cited by 105

Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study

Zhang, Z., Kang, W.-H., Li, Q., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.010 · Cited by 104

Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial

Corrigan, M. H. N., Gallen, C. C., Bonura, M. L., & Merchant, K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.10.004 · Cited by 104

The current status of neuroleptic therapy.

Kane, J. M. (1989) · PubMed · Cited by 104

The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial

Fleischhacker, W. W., Keet, I. P. M., & Kahn, R. S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.06.004 · Cited by 102

Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia.

Lieberman, J. A. (1999) · PubMed · Cited by 102

An Update of Fast-Off Dopamine D2 Atypical Antipsychotics

Seeman, P. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1984-a · Cited by 101

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline

Fujita, Y., Ishima, T., Kunitachi, S., Hagiwara, H., Zhang, L., Iyo, M., & Hashimoto, K. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.031 · Cited by 100

Comparison of biochemical effects of statins and fish oil in brain: The battle of the titans

Farooqui, A. A., Ong, W., Horrocks, L. A., Chen, P., & Farooqui, T. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.004 · Cited by 100

Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia

den Boer, J. A., van Megen, H. J. G. M., Slaap, B. R., Westenberg, H. G. M., Fleischhacker, W. W., Louwerens, J. W., Burrows, G. D., & Srivastava, O. N. (1995) · Psychopharmacology · doi:10.1007/bf02246069 · Cited by 95

Placebo-Controlled Study of the D4/5-HT2A Antagonist Fananserin in the Treatment of Schizophrenia

Truffinet, P., Tamminga, C. A., Fabre, L. F., Meltzer, H. Y., re, M.-E. R. ⁄., & Papillon-Downey, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.419 · Cited by 94

Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats

Rezvani, A. H., Kholdebarin, E., Brucato, F. H., Callahan, P. M., Lowe, D., & Levin, E. D. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.11.018 · Cited by 94

A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia

Shiina, A., Shirayama, Y., Niitsu, T., Hashimoto, T., Yoshida, T., Hasegawa, T., Haraguchi, T., Kanahara, N., Shiraishi, T., Fujisaki, M., et al. (2010) · Annals of General Psychiatry · doi:10.1186/1744-859x-9-27 · Cited by 94

Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia

Wüstenberg, T., Begemann, M., Bartels, C., Gefeller, O., Stawicki, S., Hinze‐Selch, D., Mohr, A., Falkai, P., Aldenhoff, J., Knauth, M., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.51 · Cited by 93

Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia

Duncan, G. E., Zorn, S. J., & Lieberman, J. A. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000581 · Cited by 91

Antipsychotic Drugs and their Side-Effects

(1993) · Elsevier eBooks · doi:10.1016/c2009-0-02274-0 · Cited by 90

Comparison of the Effects of Clozapine, Risperidone, and Olanzapine on Ketamine-Induced Alterations in Regional Brain Metabolism

Duncan, G. E., Miyamoto, S., Leipzig, J. N., & Lieberman, J. A. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39197-9 · Cited by 90

Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings

Fields, R. B., Van Kammen, D. P., Peters, J. L., Rosen, J., Van Kammen, W. B., Nugent, A., Stipetic, M., & Linnoila, M. (1988) · Schizophrenia Research · doi:10.1016/0920-9964(88)90024-2 · Cited by 88

A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia

Lee, S.-W., Lee, J.-G., Lee, B. J., & Kim, Y. H. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3280117feb · Cited by 88

D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.

Remington, G. J., & Kapur, S. (1999) · PubMed · Cited by 88

Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature

Stone, J. M., Davis, J. M., Leucht, S., & Pilowsky, L. S. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn009 · Cited by 88

Metabotropic Glutamate Receptors: Potential Drug Targets for the Treatment of Schizophrenia

Chavez-Noriega, L. E., Schaffhauser, H., & Campbell, U. C. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007023339337 · Cited by 87

Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release

Cosi, C., Carilla-Durand, E., Assié, M. B., Ormière, A.-M., Maraval, M., Leduc, N., & Newman‐Tancredi, A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.01.051 · Cited by 87

A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia

Mu, Q., Johnson, K. A., Morgan, P. S., Grenesko, E. L., Molnar, C., Anderson, B. S., Nahas, Z. H., Kozel, F. A., Köse, S., Knable, M. B., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.033 · Cited by 87

Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [ 123 I]epidepride single photon emission tomography (SPET) study

Bigliani, V., Mulligan, R. S., Acton, P. D., Ohlsen, R. I., Pike, V. W., Ell, P. J., Gacinovic, S., Kerwin, R. W., & Pilowsky, L. S. (2000) · Psychopharmacology · doi:10.1007/s002130000435 · Cited by 86

Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia

Kim, D. H., Maneen, M. J., & Stahl, S. M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.020 · Cited by 85

A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia

George, M. S., Molnar, C., Grenesko, E. L., Anderson, B. S., Mu, Q., Johnson, K. A., Nahas, Z. H., Knable, M. B., FERNANDES, P. B., Juncos, J. L., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.011 · Cited by 85

Schizophrenia: Moving Beyond Monoamine Antagonists

Conn, P. J., Tamminga, C. A., Schoepp, D. D., & Lindsley, C. W. (2008) · Molecular Interventions · doi:10.1124/mi.8.2.7 · Cited by 84

Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment

Watson, D. J., Marsden, C. A., Millan, M. J., & Fone, K. C. F. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000435 · Cited by 83

Improved P50 Auditory Gating With Ondansetron in Medicated Schizophrenia Patients

Adler, L. E., Cawthra, E. M., Donovan, K. A., Harris, J. G., Nagamoto, H. T., D, A. O. M., & Waldo, M. C. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.386 · Cited by 82

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

Abbas, A. I., & Roth, B. L. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802532707 · Cited by 81

Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: A randomized, double-blind placebo controlled trial

Strous, R. D., Stryjer, R., Maayan, R., Gal, G., Viglin, D., Katz, E., Eisner, D., & Weizman, A. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2006.11.002 · Cited by 81

Effects of 5‐HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat

Marcos, B., Chuang, T. T., Gil-Bea, F. J., & Ramírez, M. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.281 · Cited by 79

The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action

Wong, E. H. F., Tarazi, F. I., & Shahid, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.001 · Cited by 78

Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study

Akhondzadeh, S., Malek-Hosseini, M., Ghoreishi, A., Raznahan, M., & Rezazadeh, S. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.08.020 · Cited by 77

Optimizing Limbic Selective D2/D3 Receptor Occupancy by Risperidone: A [123I]-Epidepride SPET Study

Bressan, R. A., Erlandsson, K., JONES, H. M., Mulligan, R. S., Ell, P. J., & Pilowsky, L. S. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00002 · Cited by 77

Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys

Schneider, J. S., Sun, Z., & Roeltgen, D. P. (1994) · Brain Research · doi:10.1016/0006-8993(94)90471-5 · Cited by 75

Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia

Levkovitz, Y., Levi, U., Braw, Y., & Cohen, H. (2007) · Brain Research · doi:10.1016/j.brainres.2007.03.080 · Cited by 75

5-HT6 Receptor Antagonists as Potential Therapeutics for Cognitive Impairment

Rossé, G., & Schaffhauser, H. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790411036 · Cited by 75

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia

Lindenmayer, J., & Khan, A. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.08.021 · Cited by 74

Therapeutic Potential of 5-HT2CReceptor Ligands

Hovelsø, N., Cremers, T. I. F. H., & Sotty, F. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.180 · Cited by 73

Food Intake‐independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism

Cota, D., Sandoval, D. A., Olivieri, M., Prodi, E., D’Alessio, D. A., Woods, S. C., Seeley, R. J., & Obici, S. (2009) · Obesity · doi:10.1038/oby.2009.84 · Cited by 72

Challenges for and current status of research into positive modulators of AMPA receptors

Ward, S. E., Bax, B. D., & Harries, M. H. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00726.x · Cited by 72

M-100907 (Aventis).

de Paulis, T. (2001) · PubMed · Cited by 71

Emerging drugs for schizophrenia

Agid, O., Kapur, S., & Remington, G. J. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.3.479 · Cited by 71

High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia

Dyer, M. A., Freudenreich, O., Maravić, M. C., Pachas, G. N., Deckersbach, T., MURPHY, E., GOFF, D. C., & Evins, A. E. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.491 · Cited by 71

Differences in agonist/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ 208-912

Tadori, Y., Kitagawa, H., Forbes, R. A., McQuade, R. D., Stark, A., & Kikuchi, T. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.07.031 · Cited by 69

Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

Marenco, S., Egan, M. F., Goldberg, T. E., Knable, M. B., McClure, R. K., Winterer, G., & Weinberger, D. R. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00311-5 · Cited by 69

Catechol 0-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats

Liljequist, R., Haapalinna, A., Ahlander, M., Li, Y. H., & Männistö, P. T. (1997) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)80989-8 · Cited by 69

Pharmacotherapy for treatment-resistant schizophrenia

Harrison, J., McIlwain, M., Wheeler, A., & Russell (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s12769 · Cited by 68

COMT inhibitors and liver toxicity.

Watkins, P. B. (2000) · PubMed · Cited by 67

Improvement of Sustained Attention and Visual and Movement Skills, but Not Clinical Symptoms, After Dehydroepiandrosterone Augmentation in Schizophrenia: A Randomized, Double-blind, Placebo-controlled, Crossover Trial

Ritsner, M. S., Gibel, A., Ratner, Y., Tsinovoy, G., & Strous, R. D. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000237942.50270.35 · Cited by 66

Involvement of GABA systems in acetylcholine release induced by 5-HT3 receptor blockade in slices from rat entorhinal cortex

Ramírez, M. J., Cenarruzabeitia, E., Lasheras, B., & del Rı́o, J. A. (1996) · Brain Research · doi:10.1016/0006-8993(95)01471-3 · Cited by 66

The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review

Thornton, A. E., Snellenberg, J. X. V., Sepehry, A. A., & Honer, W. G. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881105057002 · Cited by 64

Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia: A Randomized, Double-Blind, Pilot Study

Kelly, D. L., Gorelick, D. A., Conley, R. R., Boggs, D. L., Linthicum, J., Liu, F., Feldman, S. M., Ball, M. P., Wehring, H. J., McMahon, R. P., et al. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318204825b · Cited by 62

5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus

Li, Z., Huang, M., Prus, A. J., Dai, J., & Meltzer, H. Y. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.060 · Cited by 61

Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the α7 nicotinic acetylcholine receptor: In vitro and in vivo activity

Acker, B. A., Jacobsen, E. J., Rogers, B. N., Wishka, D. G., Reitz, S. C., Piotrowski, D. W., Myers, J. K., Wolfe, M. L., Groppi, V. E., Thornburgh, B. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.070 · Cited by 61

Dopamine agonists in schizophrenia: a review

Benkert, O., Muller-Siecheneder, F., & Wetzel, H. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)00022-h · Cited by 60

Impact of Schizophrenia and Chronic Antipsychotic Treatment on [123I]CNS-1261 Binding to N-Methyl-D-Aspartate Receptors In Vivo

Bressan, R. A., Erlandsson, K., Stone, J. M., Mulligan, R. S., Krystal, J. H., Ell, P. J., & Pilowsky, L. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.016 · Cited by 60

Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.

Newman‐Tancredi, A., Cussac, D., & Depoortère, R. (2007) · PubMed · Cited by 60

Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia

Singh, V., Singh, S. P., & Chan, K. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990654 · Cited by 58

Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST)

Volavka, J., Czobor, P., Derks, E. M., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06529 · Cited by 56

Adjunctive α2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission

Marcus, M. M., Wiker, C., Frånberg, O., Konradsson‐Geuken, Å., Langlois, X., Jardemark, K. E., & Svensson, T. H. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990794 · Cited by 56

Antipsychotic-associated neuronal changes in the brain: Toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia?

Dean, C. E. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.08.019 · Cited by 55

Alpha-2 Adrenoceptor Activation Inhibits Phencyclidine-Induced Deficits of Spatial Working Memory in Rats

Marrs, W., Kuperman, J. M., Avedian, T., Roth, R. H., & Jentsch, J. D. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300700 · Cited by 55

Negative symptoms: diagnosis, treatment and prognosis

Buchanan, R. W., & Gold, J. M. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199605002-00002 · Cited by 55

Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive α2 adrenoceptor blockade: experimental evidence

Wadenberg, M.-L. G., Wiker, C., & Svensson, T. H. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006638 · Cited by 55

Deconstructing Schizophrenia

Holden, C. (2003) · Science · doi:10.1126/science.299.5605.333 · Cited by 54

Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial

Boggs, D. L., Kelly, D. L., McMahon, R. P., Gold, J. M., Gorelick, D. A., Linthicum, J., Conley, R. R., Liu, F., Waltz, J. A., Huestis, M. A., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.009 · Cited by 54

Recent advances in histamine H3receptor antagonists/inverse agonists

Łażewska, D., & Kieć‐Kononowicz, K. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.509346 · Cited by 53

NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia

Karle, J., Lublin, H., Gerlach, J., Clemmesen, L., Hansen, L., Andersen, M. Ø., Andersen, J., Fensbo, C., Sloth-Nielsen, M., & Skrumsager, B. K. (1995) · Psychopharmacology · doi:10.1007/bf02246071 · Cited by 52

SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity

Depoortère, R., Boulay, D., Perrault, G., Bergis, O. E., Decobert, M., Françon, D., Jung, M., Simiand, J., Soubrié, P., & Scatton, B. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300261 · Cited by 52

Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial

Nachshoni, T., Ebert, T., Abramovitch, Y., Assael-Amir, M., Kotler, M., Maayan, R., Weizman, A., & Strous, R. D. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.029 · Cited by 51

Multifunctional Drugs: A Novel Concept for Psychopharmacology

Stahl, S. M. (2009) · CNS Spectrums · doi:10.1017/s1092852900000213 · Cited by 50

Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia

Tregellas, J. R., D, A. O. M., Johnson, L. L., Tanabe, J., Shatti, S., Martín, L., Singel, D., Du, Y. P., Soti, F. S., Kem, W. R., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.196 · Cited by 50

Serotonergic approaches in the development of novel antipsychotics

Jones, C. A., & McCreary, A. C. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.025 · Cited by 50

The effect of Ondansetron on memory in schizophrenic patients

Levkovitz, Y., Arnest, G., Mendlovic, S., Treves, I., & Fennig, S. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2003.09.022 · Cited by 49

Symptom domains of schizophrenia: the role of atypical antipsychotic agents

Burton, S. C. (2006) · Journal of Psychopharmacology · doi:10.1177/1359786806071237 · Cited by 49

Tolcapone-Related Liver Dysfunction

Borges, N. (2003) · Drug Safety · doi:10.2165/00002018-200326110-00001 · Cited by 46

Cognitive Improvement in Response to Antipsychotic Drugs

Heinrichs, R. W. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.631 · Cited by 46

The American Psychiatric Press Textbook of Psychopharmacology

Baron, D. A. (1996) · Psychiatric Services · doi:10.1176/ps.47.2.203-a · Cited by 46

Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 > D2 Antagonist, S33138

Millan, M. J., & Brocco, M. (2008) · Therapies · doi:10.2515/therapie:2008041 · Cited by 45

Polyunsaturated fatty acid supplementation for schizophrenia

Joy, C., Mumby-Croft, R., & Joy, L. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001257 · Cited by 45

Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS 67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats

Lamirault, L., Guillou, C., Thal, C., & Simon, H. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00351-2 · Cited by 44

Oestrogen — a new treatment approach for schizophrenia?

Kulkarni, J. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02373.x · Cited by 44

Biological Perspectives

Keltner, N. L., & Johnson, V. (2002) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.2002.tb01566.x · Cited by 43

Current Issues in the Psychopharmacology of Schizophrenia

Cheung, H. K. (2002) · Hong Kong journal of psychiatry · Cited by 42

New drugs for the treatment of schizophrenic patients

Fleischhacker, W. W. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb05941.x · Cited by 42

A Double-Blind, Randomized, Placebo-Controlled Study of the Dopamine D3 Receptor Antagonist ABT-925 in Patients With Acute Schizophrenia

Redden, L., Rendenbach‐Mueller, B., Abi‐Saab, W., Katz, D. A., Goenjian, A. K., Robieson, W., Wang, Y., Goss, S. L., Greco, N., & Saltarelli, M. D. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e4818 · Cited by 42

Schizophrenia and mood disorders : the new drug therapies in clinical practice

Buckley, P. F., & Waddington, J. L. (1999) · Cited by 41

Novel Targets for Drugs in Schizophrenia

Stone, J. M., & Pilowsky, L. S. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707781387323 · Cited by 41

Kinetic modelling of [123I]CNS 1261—a potential SPET tracer for the NMDA receptor

Erlandsson, K., Bressan, R. A., Mulligan, R. S., Gunn, R. N., Cunningham, V. J., Owens, J., Wyper, D. J., Ell, P. J., & Pilowsky, L. S. (2003) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(02)00450-x · Cited by 40

Metabotropic Glutamate Receptors as Therapeutic Targets for Cognitive Disorders

Gravius, A., Pietraszek, M., Dekundy, A., & Danysz, W. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790411018 · Cited by 39

Pharmacological Strategies for Enhancing Cognition in Schizophrenia

Barch, D. M. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_39 · Cited by 38

Effects of the D 3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia

Lahti, A. C., Weiler, M. A., Carlsson, A., & Tamminga, C. A. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050091 · Cited by 38

The course of brain abnormalities in schizophrenia: can we slow the progression?

van Haren, N. E. M., Cahn, W., Pol, H. E. H., & Kahn, R. S. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111408964 · Cited by 38

Current issues in the psychopharmacology of schizophrenia

Breier, A. F., Tran, P., Herrera, J. M., Tollefson, G. D., & Bymaster, F. P. (2001) · Lippincott Williams & Wilkins eBooks · Cited by 38

The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia

Conley, R. R., Boggs, D. L., Kelly, D. L., McMahon, R. P., Dickinson, D., Feldman, S. M., Ball, M. P., & Buchanan, R. W. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31816f2795 · Cited by 35

Dosing Atypical Antipsychotics

Cutler, A. J., Ball, S., & Stahl, S. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900003035 · Cited by 35

Drugs in development for the treatment of schizophrenia

Emsley, R. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903066756 · Cited by 33

Chronic Administration of Haloperidol and Olanzapine Attenuates Ketamine-Induced Brain Metabolic Activation

Duncan, G. E., Miyamoto, S., & Lieberman, J. A. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048140 · Cited by 32

Blockade of neurokinin3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs

Gueudet, C., Santucci, V., Soubri�, P., & Fur, G. L. (1999) · Synapse · doi:10.1002/(sici)1098-2396(199907)33:1<71::aid-syn7>3.0.co;2-2 · Cited by 29

Therapeutic Utility of NK3 Receptor Antagonists for the Treatment of Schizophrenia

Dawson, L. A., & Smith, P. W. (2009) · Current Pharmaceutical Design · doi:10.2174/138161210790170067 · Cited by 29

The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats

Bubeníková‐Valešová, V., Svoboda, J., Horáček, J., & Valeš, K. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009851 · Cited by 28

Handbook of Contemporary Neuropharmacology

Brown, W. A., Solomon, D. A., & Khan, A. O. (2007) · JAMA · doi:10.1001/jama.298.22.2682 · Cited by 27

Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia

Sacco, K. A., Creeden, C. L., Reutenauer, E. L., & George, T. P. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.05.004 · Cited by 27

Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone

Crocq, M. A., Набер, Д., LADER, M. H., Thibaut, F., Drici, M., Everitt, B. J., Hall, G. C., Jeunne, C. L., Mittoux, A., Peuskens, J., et al. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.09.001 · Cited by 26

Antipsychotic Drug Development

Kim, D. H., & Stahl, S. M. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_47 · Cited by 25

Secretin Effects on Cerebellar-Dependent Motor Learning in Schizophrenia

Bolbecker, A. R., Hetrick, W. P., Johannesen, J., O’Donnell, B. F., Steinmetz, J. E., & Shekhar, A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08040597 · Cited by 25

Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients

Corsini, G. U., Bonuccelli, U., Rainer, E., & Zompo, M. D. (1985) · Journal of Neural Transmission · doi:10.1007/bf01245972 · Cited by 22

Inhibition of fear potentiated startle in rats following peripheral administration of secretin

Myers, K. M., Goulet, M., Rusche, J. R., Boismenu, R., & Davis, M. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1633-5 · Cited by 21

Emerging drugs for schizophrenia

Biedermann, F., & Fleischhacker, W. W. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.556112 · Cited by 21

New Developments in the pharmacotherapy of schizophrenia

Fleischhacker, W. W. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6020-6_7 · Cited by 20

S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.

Millan, M. J., Gobert, A., Newman‐Tancredi, A., Lejeune, F., Cussac, D., Rivet, J., Audinot, V., Adhumeau-Auclair, A., Brocco, M., Nicolas, J., et al. (2000) · PubMed · Cited by 19

PRE- AND POSTSYNAPTIC D1 TO D5 DOPAMINE RECEPTOR MECHANISMS IN RELATION TO ANTIPSYCHOTIC ACTIVITY

Waddington, J. L. (1993) · Elsevier eBooks · doi:10.1016/b978-0-12-079035-7.50011-7 · Cited by 18

Osanetant Sanofi-Synthélabo.

Kamali, F. (2001) · PubMed · Cited by 17

SB-277011 GlaxoSmithKline.

Remington, G. J., & Kapur, S. (2001) · PubMed · Cited by 16

Antipsychotics in the early stage of development

Biedermann, F., & Fleischhacker, W. W. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328329cd73 · Cited by 14

Partial Reversal of Phencyclidine-Induced Impairment of Prepulse Inhibition by Secretin

Myers, K. M., Goulet, M., Rusche, J. R., Boismenu, R., & Davis, M. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.023 · Cited by 12

Pharmacotherapy of Schizophrenia

Sharif, Z. A., Miyamoto, S., & Lieberman, J. A. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn033 · Cited by 5

Schizophrenia

Owen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870

Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration

Dinan, T. G., & Cryan, J. F. (2017) · The Journal of Physiology · doi:10.1113/jp273106 · Cited by 813

Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial

McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617

Polypharmacology – Foe or Friend?

Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465

Trace Amines and Their Receptors

Gainetdinov, R. R., Hoener, M. C., & Berry, M. D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015305 · Cited by 384